Why IMU is a multi multi bagger, page-12203

This says it all

w"How many billions of dollars is dependent largely on the business acumen of Imugene’s Chief of Business Monil Shah, who along with Hopper and the company’s Chief Financial Officer Mike Tonroe, have been assigned the task of cutting a deal with Big Pharma in the drugs now phase 2 development stage. Obviously much is sure to depend on the current Her Vaxx/Keytruda combination trial results, but keep in mind sound cancer drugs sell for between 3 to 4 times annualised peak sales. Her Vaxx’s extensive trademark coverage in addition to its potential to act in breast, gastric and other lucrative cancer markets, are all factors assisting Shah and his team to secure a pultis for IMU shareholders, when all is said and done. Fingers crossed….

Imugene’s B cell value is enhanced by the company’s second B cell candidate PD1 Vaxx, a drug that recently exhibited strong results in a Phase 1 clinical trial for late stage lung cancer patients in Melbourne. The drugs administration resulted in a complete response for one patient, who is now cancer free, as well as many partial responses and disease stabilisation outcomes for these very sick patients. The PD1 Vaxx results have led to a supply agreement being solidified with the Big Pharma Roche, who is soon to supply their successful Tercentriq drug with Imugene’s PD1 Vaxx in a trial for lung cancer patients. Lung cancer is a prevalent form of cancer, particularly in Asia and throughout the US, where patients up til now have poor life expectancy when presenting in the late stages of their disease. PD1 Vaxx’s advancement to this combination trial with Roche is not only proof of concept for Imugene’s B cell platform, it is another string to Monil Shah’s bow, when it comes to securing a potential deal with a Big Pharma suitor."

But hey, IMUGENE isn't in the business of marketing or selling their drugs ?